Pharvaris Published Analysis of HAE Care Gaps
New research highlights critical discrepancies between clinical guidelines and patient experiences in managing hereditary angioedema.
Updated on Oct. 6, 2026 in Allergies
Live Poll
Should treatment convenience be as important as clinical effectiveness when choosing a chronic disease medication?
A recent analysis published in Advances in Therapy examined real-world patterns of hereditary angioedema (HAE) management across the United States, Europe, and Japan. The study reveals that patient treatment satisfaction is significantly influenced by portability, the route of administration, and the burden of injectable options.
Why it matters
The findings underscore why many patients choose to avoid treating every HAE attack, often citing pain from injections or the perceived lack of severity. Understanding these barriers is essential for developing medical solutions that align better with the daily preferences and needs of HAE patients.
The study analyzed data from 1,131 patients evaluated by 225 physicians, with 279 patients providing direct self-reported insights into their treatment patterns. Researchers captured this information during a retrospective survey period spanning January 2023 to January 2024.
The players
Pharvaris
A biopharmaceutical company based in Zug, Switzerland, focused on developing treatments for bradykinin-mediated angioedema.
Advances in Therapy
A peer-reviewed medical journal that publishes research and clinical insights across various therapeutic areas.
The details
The study suggests that daily oral treatments are preferred over injectable prophylaxis, as patients frequently avoid injections due to pain and difficulty of use. Pharvaris intends to use these insights to inform future care solutions and establish a new standard for managing bradykinin-mediated angioedema.
Timeline
Data for the survey were collected between January 2023 and January 2024.
The analysis was published in Advances in Therapy on October 5, 2026.
Health Landscape
This analysis relies on data from the Adelphi Real World HAE Disease Specific Programme to map how patients actually navigate their condition compared to clinical ideals. It reflects a growing industry trend of prioritizing patient-reported burdens to refine therapeutic design.
Patients dealing with hereditary angioedema may find this analysis validates common struggles with injectable treatments and administration pain. These insights suggest a shift toward valuing oral, portable medication options that minimize the daily burden of care.
The takeaway
Patients who find injectable treatments overly burdensome should consult their healthcare provider about emerging oral alternatives that may better suit their lifestyle. Recognizing these treatment barriers is a critical step for patients to take in advocating for more manageable disease control plans.
Further reading
For more information on managing chronic conditions, visit our Allergies section.
More information
Access the full publication of study analysis for detailed findings.
Live Poll
Should treatment convenience be as important as clinical effectiveness when choosing a chronic disease medication?
